Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC

Introduction: Although programmed cell death protein 1 and programmed death-ligand 1 (PD-L1) blockade in com-bination with platinum-doublet chemotherapy has become a mainstay of first-line treatment for advanced NSCLC, fac-tors associated with efficacy of chemoimmunotherapy (CIT) are not well characterized.Methods: In this multicenter retrospective analysis, clini-copathologic and genomic data were collected from patients with advanced NSCLC (lacking sensitizing genomic alter-ations in EGFR and ALK) and evaluated with clinical out-comes to first-line CIT. Results: Among 1285 patients treated with CIT, a worsening performance status and increasing derived neutrophil-to-lymphocyte ratio in the blood were associated with a signif-icantly reduced objective response rate (ORR), median progression-free survival (mPFS), and median overall sur-vival (mOS). With increasing PD-L1 tumor proportion scores of less than 1%, 1% to 49%, 50% to 89%, and greater than or equal to 90%, there was a progressive improvement in ORR (32.7% versus 37.5% versus 51.6% versus 61.7%, p < 0.001), mPFS (5.0 versus 6.1 versus 6.8 versus 13.0 mo, p < 0.001), and generally mOS (12.9 versus 14.6 versus 34.7 versus 23.1 mo, p = 0.009), respectively. Of 789 NSCLCs with comprehensive genomic data, NSCLCs with a tumor mutational burden (TMB) greater than or equal to the 90th percentile had an improved ORR (53.5% versus 36.4%, p = 0.004), mPFS (10.8 versus 5.5 mo, p < 0.001), and mOS (29.2 versus 13.1 mo, p < 0.001), compared with those with a TMB less than the 90th percentile. In all-comers with nonsquamous NSCLC, the presence of an STK11, KEAP1, or SMARCA4 mutation was associated with significantly worse ORR, mPFS, and mOS to CIT (all p < 0.05); this was also observed in the KRAS-mutant subgroup of NSCLCs with co-occurring mutations in STK11, KEAP1, or SMARCA4 (all p < 0.05). In KRAS wild-type NSCLC, KEAP1 and SMARCA4 mutations were associated with a significantly shorter mPFS and mOS to CIT (all p < 0.05), but STK11 mutation status had no significant impact on mPFS (p = 0.16) or mOS (p = 0.38).Conclusions: In advanced NSCLC, better patient perfor-mance status, low derived neutrophil-to-lymphocyte ratio, increasing PD-L1 expression, a very high TMB, and STK11/ KEAP1/SMARCA4 wild-type status are associated with improved clinical outcomes to first-line CIT. (c) 2023 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.